Bayer Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bayer (Whippany, NJ): 39 reconciled FDA prescription therapies (6.2% 2025 to 2030 cliff risk), $2.92B 2024 CMS Part D & Medicaid spend, and 42 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWhippany, NJ
Reconciled FDA Portfolio Therapies39
2025 to 2030 Patent-Cliff Revenue Exposure6.2%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$2.92B
2024 Medicare Part D Spend$2.33B
2024 Medicaid Spend$592.3M
California HCAI SB 17 Filings42 WAC filings (max 22.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.